GSK Acquires RAPT Therapeutics for $2.2 Billion to Advance Food Allergy Treatment
核心洞察
GSK has agreed to acquire RAPT Therapeutics for $2.2 billion to gain control of ozureprubart, a potentially best-in-class anti-IgE (搜索) antibody for food allergy protection.
Ozureprubart offers potential for less frequent dosing every 12 weeks compared to current standard-of-care therapy requiring injections every 2-4 weeks.
The acquisition addresses significant unmet medical need, with over 17 million people diagnosed with food allergies in the US and more than 1.3 million suffering severe reactions.
GSK has announced a definitive agreement to acquire RAPT Therapeutics for $2.2 billion, marking the first major acquisition under new CEO Luke Miels. The deal centers on ozureprubart, a long-acting anti-immunoglobulin E (IgE (搜索)) monoclonal antibody currently in phase IIb clinical development for prophylactic protection against food allergens.
The acquisition represents a strategic move to strengthen GSK's respiratory, immunology, and inflammation pipeline. According to Tony Wood, GSK's Chief Scientific Officer, "The addition of ozureprubart brings another promising new, potential best-in-class treatment to GSK's pipeline. Ozureprubart offers the opportunity to bring sustained protection to patients with dosing every 12 weeks, and is consistent with our approach to acquire assets that address validated targets and where there is clear unmet medical need."
Addressing Critical Treatment Gaps
Food allergies represent a significant and growing health burden, with around 94% of severe food allergies caused by IgE (搜索)-mediated reactions. In the US alone, over 17 million people are diagnosed with food allergies, with more than 1.3 million people suffering severe reactions. Notably, 65% of severe food allergy patients are children and adolescents, resulting in more than 3 million patient visits each year to hospital and emergency care.
Current anti-IgE (搜索) treatment for food allergy involves injections every 2 to 4 weeks, which can be a significant burden, particularly for pediatric patients. Ozureprubart's clinical profile offers the potential for less frequent dosing of every 12 weeks, supporting improved compliance and patient outcomes. Additionally, the new antibody could provide a treatment option for approximately 25% of patients currently ineligible for existing therapy.
Competitive Positioning
If approved, ozureprubart could compete with Genentech/Novartis' established anti-IgE (搜索) drug Xolair (omalizumab), which had prevention of food allergies added to its label in the US two years ago. The potential for extended dosing intervals represents a major differentiator, particularly important given that food allergy treatment mostly affects children.
IgE (搜索) is a clinically validated target and represents the only approved systemic therapy shown to protect patients from harmful allergic and inflammatory immune responses. Ozureprubart was originally created and developed by China's Shanghai Jemincare Pharma (搜索) and is also being developed for chronic spontaneous urticaria and asthma.
Development Timeline and Financial Terms
Data from the phase IIb prestIgE trial of ozureprubart as monotherapy for food allergies is expected in 2027, followed by a phase III trials program focused on both at-risk adult and pediatric populations. Under the terms of the agreement, GSK will pay RAPT Therapeutics shareholders $58.00 per share at closing, with a net upfront investment of $1.9 billion after accounting for cash acquired.
The transaction gives GSK global rights to the ozureprubart program, excluding mainland China, Macau, Taiwan, and Hong Kong. GSK will also be responsible for success-based milestone and royalty payments for ozureprubart owed to RAPT's partner, Shanghai Jeyou Pharmaceutical Co., Ltd. (搜索)
Economic Impact
The economic burden of food allergies is substantial, costing US families an estimated $33 billion in 2024. Disease burden is amplified by the frequency and complexity of allergic reactions, which can escalate to anaphylaxis, emergency care, and impact patient wellbeing and participation in social activities.
Brian Wong, President and CEO of RAPT Therapeutics, commented: "We are excited to enter into this agreement with GSK, which offers an attractive path forward for our programs, particularly the opportunity we envision for ozureprubart in food allergy. This transaction has the potential to provide access to the global development and commercialization capabilities, resources and infrastructure that GSK has to offer."
The transaction is expected to close in the first quarter of 2026, subject to customary closing conditions including regulatory approvals and the tender of a majority of RAPT's outstanding shares.